KR20200136957A - 헤테로사이클릭 화합물 및 이의 용도 - Google Patents
헤테로사이클릭 화합물 및 이의 용도 Download PDFInfo
- Publication number
- KR20200136957A KR20200136957A KR1020207030605A KR20207030605A KR20200136957A KR 20200136957 A KR20200136957 A KR 20200136957A KR 1020207030605 A KR1020207030605 A KR 1020207030605A KR 20207030605 A KR20207030605 A KR 20207030605A KR 20200136957 A KR20200136957 A KR 20200136957A
- Authority
- KR
- South Korea
- Prior art keywords
- group
- optionally substituted
- compound
- atom
- nitrogen atom
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4833—Encapsulating processes; Filling of capsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018062939 | 2018-03-28 | ||
| JPJP-P-2018-062939 | 2018-03-28 | ||
| PCT/JP2019/014901 WO2019189945A1 (en) | 2018-03-28 | 2019-03-27 | Heterocyclic compound and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20200136957A true KR20200136957A (ko) | 2020-12-08 |
Family
ID=66397395
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020207030605A Ceased KR20200136957A (ko) | 2018-03-28 | 2019-03-27 | 헤테로사이클릭 화합물 및 이의 용도 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US10807987B2 (https=) |
| EP (1) | EP3774800B1 (https=) |
| JP (1) | JP7279067B2 (https=) |
| KR (1) | KR20200136957A (https=) |
| CN (1) | CN111936495A (https=) |
| AR (1) | AR115020A1 (https=) |
| AU (1) | AU2019241765B2 (https=) |
| BR (1) | BR112020018238A2 (https=) |
| CA (1) | CA3100133A1 (https=) |
| EA (1) | EA202092294A1 (https=) |
| ES (1) | ES3006012T3 (https=) |
| IL (1) | IL276912A (https=) |
| MA (1) | MA52214A (https=) |
| MX (1) | MX2020010148A (https=) |
| SG (1) | SG11202008519RA (https=) |
| TW (1) | TW202003519A (https=) |
| WO (1) | WO2019189945A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3660003B1 (en) | 2017-07-28 | 2024-01-24 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| US10807987B2 (en) * | 2018-03-28 | 2020-10-20 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof |
| JP2021050161A (ja) | 2019-09-25 | 2021-04-01 | 武田薬品工業株式会社 | 複素環化合物及びその用途 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2492382A1 (fr) * | 1980-10-22 | 1982-04-23 | Synthelabo | Derives d'imidazo (1,2-a) pyridine, leur preparation et leur application en therapeutique |
| US5252563A (en) * | 1991-12-19 | 1993-10-12 | G. D. Searle & Company | 5,6,7,8-tetrahydro-imidazo[1,2-a]pyrimidine compounds for treatment of neurotoxic injury |
| JP3439551B2 (ja) * | 1994-11-08 | 2003-08-25 | 富士写真フイルム株式会社 | ハロゲン化銀写真感光材料 |
| EP0815134B1 (en) | 1995-03-14 | 2002-06-05 | Praecis Pharmaceuticals Incorporated | Modulators of amyloid aggregation |
| PT929574E (pt) | 1996-08-27 | 2005-11-30 | Praecis Pharm Inc | Moduladores da agregacao de peptidos beta-amiloides compreendendo d-aminoacidos |
| US6331640B1 (en) | 1998-10-13 | 2001-12-18 | Hoffmann-La Roche Inc. | Diaminopropionic acid derivatives |
| EP1196609A2 (en) | 1999-06-28 | 2002-04-17 | Oklahoma Medical Research Foundation | Catalytically active recombinant memapsin and methods of use thereof |
| WO2002080928A1 (en) * | 2001-04-03 | 2002-10-17 | Merck & Co., Inc. | N-substituted nonaryl-heterocyclo amidyl nmda/nr2b antagonists |
| JP2004161716A (ja) * | 2002-11-15 | 2004-06-10 | Takeda Chem Ind Ltd | Ｊｎｋ阻害剤 |
| MXPA05010824A (es) * | 2003-04-10 | 2005-12-05 | Pfizer | Compuestos biciclicos como antagonistas del receptor nr2b. |
| EP1919872A4 (en) | 2005-08-31 | 2009-08-05 | Smithkline Beecham Corp | CHEMICAL COMPOUNDS |
| MX2011008276A (es) * | 2009-02-06 | 2011-12-14 | Elan Pharm Inc | Inhibidores de quinasa jun n-terminal. |
| US8404859B2 (en) | 2011-03-16 | 2013-03-26 | Hoffmann-La Roche Inc. | Thiazole and thiophene compounds |
| ES2581848T3 (es) * | 2011-04-05 | 2016-09-07 | Pfizer Limited | Derivados de pirrolo[2,3-d]pirimidina como inhibidores de quinasas relacionadas con tropomiosina |
| FR2998892B1 (fr) | 2012-12-04 | 2015-01-02 | Pf Medicament | Derives d'aminocyclobutane, leur procede de preparation et leur utilisation a titre de medicaments |
| CA2903572A1 (en) | 2013-03-15 | 2014-10-23 | Epizyme, Inc. | Substituted benzene compounds |
| US9243001B2 (en) | 2013-03-15 | 2016-01-26 | Epizyme, Inc. | Substituted benzene compounds |
| US10202376B2 (en) | 2014-12-24 | 2019-02-12 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| JP6827757B2 (ja) | 2016-10-11 | 2021-02-10 | 鬼怒川ゴム工業株式会社 | ウエザーストリップ取付用クリップ |
| EP3660003B1 (en) * | 2017-07-28 | 2024-01-24 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| US10807987B2 (en) * | 2018-03-28 | 2020-10-20 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof |
| WO2020153414A1 (ja) * | 2019-01-24 | 2020-07-30 | 武田薬品工業株式会社 | 複素環化合物及びその用途 |
| WO2020196828A1 (ja) * | 2019-03-28 | 2020-10-01 | 武田薬品工業株式会社 | 含窒素複素環化合物 |
-
2019
- 2019-03-27 US US16/366,710 patent/US10807987B2/en active Active
- 2019-03-27 JP JP2020551599A patent/JP7279067B2/ja active Active
- 2019-03-27 CN CN201980023246.1A patent/CN111936495A/zh active Pending
- 2019-03-27 ES ES19721865T patent/ES3006012T3/es active Active
- 2019-03-27 KR KR1020207030605A patent/KR20200136957A/ko not_active Ceased
- 2019-03-27 CA CA3100133A patent/CA3100133A1/en active Pending
- 2019-03-27 TW TW108110758A patent/TW202003519A/zh unknown
- 2019-03-27 EP EP19721865.4A patent/EP3774800B1/en active Active
- 2019-03-27 AU AU2019241765A patent/AU2019241765B2/en active Active
- 2019-03-27 WO PCT/JP2019/014901 patent/WO2019189945A1/en not_active Ceased
- 2019-03-27 MX MX2020010148A patent/MX2020010148A/es unknown
- 2019-03-27 BR BR112020018238-9A patent/BR112020018238A2/pt not_active IP Right Cessation
- 2019-03-27 MA MA052214A patent/MA52214A/fr unknown
- 2019-03-27 SG SG11202008519RA patent/SG11202008519RA/en unknown
- 2019-03-27 EA EA202092294A patent/EA202092294A1/ru unknown
- 2019-03-27 AR ARP190100766A patent/AR115020A1/es not_active Application Discontinuation
-
2020
- 2020-08-25 IL IL276912A patent/IL276912A/en unknown
-
2021
- 2021-03-15 US US17/201,878 patent/US11702419B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3774800C0 (en) | 2024-11-13 |
| WO2019189945A1 (en) | 2019-10-03 |
| AU2019241765A8 (en) | 2021-02-18 |
| MX2020010148A (es) | 2020-12-07 |
| TW202003519A (zh) | 2020-01-16 |
| ES3006012T3 (en) | 2025-03-17 |
| US20190300536A1 (en) | 2019-10-03 |
| WO2019189945A8 (en) | 2020-10-15 |
| EA202092294A1 (ru) | 2021-01-15 |
| US10807987B2 (en) | 2020-10-20 |
| IL276912A (en) | 2020-10-29 |
| US20210332053A1 (en) | 2021-10-28 |
| MA52214A (fr) | 2021-04-21 |
| JP2021519294A (ja) | 2021-08-10 |
| JP7279067B2 (ja) | 2023-05-22 |
| CN111936495A (zh) | 2020-11-13 |
| AR115020A1 (es) | 2020-11-18 |
| CA3100133A1 (en) | 2019-10-03 |
| SG11202008519RA (en) | 2020-10-29 |
| AU2019241765A1 (en) | 2020-11-12 |
| US11702419B2 (en) | 2023-07-18 |
| BR112020018238A2 (pt) | 2020-12-29 |
| AU2019241765B2 (en) | 2022-07-07 |
| EP3774800A1 (en) | 2021-02-17 |
| EP3774800B1 (en) | 2024-11-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3594203B1 (en) | Substituted pyrrolidine compound and use thereof | |
| EP3366679B1 (en) | Heterocyclic compound | |
| EP3239150B1 (en) | Heterocyclic compound | |
| US11230541B2 (en) | Heterocyclic compound | |
| WO2018194181A1 (en) | Heterocyclic compounds useful as modulators of acetylcholine receptors | |
| US11702419B2 (en) | Heterocyclic compound and use thereof | |
| JP7541487B2 (ja) | 複素環化合物及びその用途 | |
| JP2023502030A (ja) | 複素環式化合物およびその使用 | |
| KR20200013773A (ko) | 헤테로시클릭 화합물 | |
| EP4034257B1 (en) | Heterocyclic compound and use thereof | |
| EP4046688B1 (en) | Heterocyclic compound | |
| HK40077256B (en) | Heterocyclic compound and use thereof | |
| HK40077256A (en) | Heterocyclic compound and use thereof | |
| HK40059391A (en) | Heterocyclic compound and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| A201 | Request for examination | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
St.27 status event code: N-2-6-B10-B15-exm-PE0601 |
|
| R18 | Changes to party contact information recorded |
Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |